The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth

Journal of Molecular Medicine

Volumn 91, Issue 12, 2013, Pages 1369-1381

  Tae, Hyun Jin ^a,b   Kim, Ji Min ^a   Park, Sungha ^a,c   Tomiya, Noboru ^d   Li, Geng ^e   Wei, Wen ^a   Petrashevskaya, Natalia ^a   Ahmet, Ismayil ^a   Pang, John ^a   Cruschwitz, Stefanie ^a   Riebe, Rebecca A ^a   Zhang, Yinghua ^f   Morrell, Christopher H ^a,g   Browe, David ^a   Lee, Yuan Chuan ^d   Xiao, Rui Ping ^a,e   Talan, Mark I ^a   Lakatta, Edward G ^a   Lin, Li ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b Hallym University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e PEKING UNIVERSITY   (China)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g LOYOLA UNIVERSITY MARYLAND   (United States)

Author keywords

Arterial inflammation; Arterial injury; N glycoform; Neointimal hyperplasia; sRAGE; Therapeutic window

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CELL MARKER; GLYCAN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN S100B; SOLUBLE ADVANCED GLYCATION END PRODUCT RECEPTOR CHO; SOLUBLE ADVANCED GLYCATION END PRODUCT RECEPTOR SF9; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA; ARTICLE; BIOLOGICAL ACTIVITY; CAROTID ARTERY INJURY; CELL ASSAY; CELL MIGRATION; CHO CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; FEMALE; HYPERPLASIA; IMMUNOGENICITY; IN VIVO STUDY; INFLAMMATION; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MALE; NEOINTIMA; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; SF9 CELL; SINGLE DRUG DOSE; SMOOTH MUSCLE FIBER; TREATMENT OUTCOME; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTHRITIS; BIOLOGICAL MARKERS; CAROTID ARTERIES; CELL MOVEMENT; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GLYCOSYLATION; HUMANS; LIGANDS; MALE; MUSCLE, SMOOTH, VASCULAR; NEOINTIMA; NF-KAPPA B; RATS; RECEPTORS, IMMUNOLOGIC; RECOMBINANT PROTEINS; SF9 CELLS;

EID: 84890278553     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-1091-4     Document Type: Article

References (42)

1. Inoue T, Node K (2009) Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J 73:615-621
2. Sprague AH, Khalil RA (2009) Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 78:539-552
3. Xu CB, Sun Y, Edvinsson L (2010) Cardiovascular risk factors regulate the expression of vascular endothelin receptors. Pharmacol Ther 127:148-155
4. Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, Kalea AZ, Lu Y, Rosario RH, Oruganti S et al (2008) Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest 118:183-194
5. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 4:1025-1031
6. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B et al (2003) Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 111:959-972
7. Zhou Z, Wang K, Penn MS, Marso SP, Lauer MA, Forudi F, Zhou X, Qu W, Lu Y, Stern DM et al (2003) Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 107:2238-2243
8. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101:2652-2660
9. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889-9897
10. Lin L, Park S, Lakatta EG (2009) RAGE signaling in inflammation and arterial aging. Front Biosci 14:1403-1413
11. Degryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F, Arrigoni G, Bianchi ME (2001) The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 152:1197-1206
12. Reddy MA, Li SL, Sahar S, Kim YS, Xu ZG, Lanting L, Natarajan R (2006) Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells. J Biol Chem 281:13685-13693
13. Rouhiainen A, Kuja-Panula J, Wilkman E, Pakkanen J, Stenfors J, Tuominen RK, Lepantalo M, Carpen O, Parkkinen J, Rauvala H (2004) Regulation of monocyte migration by amphoterin (HMGB1). Blood 104:1174-1182
14. Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, Wahl P, Ziegler R, Muller M, Nawroth PP (1997) Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 96:2262-2271
15. Li J, Schmidt AM (1997) Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 272:16498-16506
16. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H (2000) The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 275:25781-25790
17. Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, Ihanus E, Ballantyne CM, Gahmberg CG, Bianchi ME, Nawroth PP et al (2007) A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 26:1129-1139
18. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S et al (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370:1097-1109
19. Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, Nawroth PP, Bierhaus A, Postina R (2008) Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 283:35507-35516
20. Wang Y, Wang H, Piper MG, McMaken S, Mo X, Opalek J, Schmidt AM, Marsh CB (2010) sRAGE induces human monocyte survival and differentiation. J Immunol 185:1822-1835
21. Varki A, Cummings RD, Esco JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME (2009) Essentials of glycobiology, 2nd edn. Cold Spring Harbor Laboratory, Cold Spring Harbor
22. Ghaderi D, Zhang M, Hurtado-Ziola N, Varki A (2012) Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev 28:147-175
23. Park SJ, Kleffmann T, Hessian PA (2011) The G82S polymorphism promotes glycosylation of the receptor for advanced glycation end products (RAGE) at asparagine 81: comparison of wild-type rage with the G82S polymorphic variant. J Biol Chem 286:21384-21392
24. Srikrishna G, Huttunen HJ, Johansson L, Weigle B, Yamaguchi Y, Rauvala H, Freeze HH (2002) N-Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. J Neurochem 80:998-1008
25. Srikrishna G, Nayak J, Weigle B, Temme A, Foell D, Hazelwood L, Olsson A, Volkmann N, Hanein D, Freeze HH (2010) Carboxylated N-glycans on RAGE promote S100A12 binding and signaling. J Cell Biochem 110:645-659
26. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, Nguyen M, Olsson A, Nawroth PP, Bierhaus A et al (2008) RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 29:2035-2043
27. Pang J, Zeng X, Xiao RP, Lakatta EG, Lin L (2009) Design, generation, and testing of mammalian expression modules that tag membrane proteins. Protein Sci 18:1261-1271
28. Tomiya N, Kurono M, Ishihara H, Tejima S, Endo S, Arata Y, Takahashi N (1987) Structural analysis of N-linked oligosaccharides by a combination of glycopeptidase, exoglycosidases, and high-performance liquid chromatography. Anal Biochem 163:489-499
29. Tae HJ, Marshall S, Zhang J, Wang M, Briest W, Talan MI (2012) Chronic treatment with a broad-spectrum metalloproteinase inhibitor, doxycycline prevents the development of spontaneous aortic lesions in a mouse model of vascular Ehlers-Danlos syndrome. J Pharmacol Exp Ther 343:246-251
30. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998-15004
31. Renard C, Chappey O, Wautier MP, Nagashima M, Lundh E, Morser J, Zhao L, Schmidt AM, Scherrmann JM, Wautier JL (1997) Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol 52:54-62
32. Leclerc E, Fritz G, Weibel M, Heizmann CW, Galichet A (2007) S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J Biol Chem 282:31317-31331
33. Reeves RH, Yao J, Crowley MR, Buck S, Zhang X, Yarowsky P, Gearhart JD, Hilt DC (1994) Astrocytosis and axonal proliferation in the hippocampus of S100b transgenic mice. Proc Natl Acad Sci U S A 91:5359-5363
34. Wei W, Lampe L, Park S, Vangara BS, Waldo GS, Cabantous S, Subaran SS, Yang D, Lakatta EG, Lin L (2012) Disulfide bonds within the C2 domain of RAGE play key roles in its dimerization and biogenesis. PLoS One 7:e50736
35. Lee YC (1992) Biochemistry of carbohydrate-protein interaction. FASEB J 6:3193-3200
36. Dam TK, Brewer CF (2010) Maintenance of cell surface glycan density by lectin-glycan interactions: a homeostatic and innate immune regulatory mechanism. Glycobiology 20:1061-1064
37. Dam TK, Brewer CF (2010) Multivalent lectin-carbohydrate interactions energetics and mechanisms of binding. Adv Carbohydr Chem Biochem 63:139-164
38. Durocher Y, Butler M (2009) Expression systems for therapeutic glycoprotein production. Curr Opin Biotechnol 20:700-707
39. Werner RG, Kopp K, Schlueter M (2007) Glycosylation of therapeutic proteins in different production systems. Acta Paediatr Suppl 96:17-22
40. Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81:1-5
41. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI (2003) Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A 100:11612-11617
42. Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI (2005) Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drugs Ther 19:243-250